Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Closure of Trading Window

 This is to inform you that pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and the Company's Code of Conduct framed under the said provisions, the Trading Window for dealing in securities of the Company shall remain closed for the Designated Persons and their immediate relatives from Saturday, October 01, 2022 till 48 hours after the declaration of Un-audited Financial Results of the Company for the quarter and half year ended September 30, 2022. The date of meeting of the Board of Directors to consider and approve the Un-audited Financial Results of the Company for the quarter and half year ended September 30, 2022 will be intimated in due course.
29-09-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to the Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Investor/Analyst call of the Company organised by M/s. Equirus Securities Private Limited is scheduled to be held on Thursday, September 22, 2022 The schedule of the aforementioned meeting is subject to change and the changes may occur due to exigencies on the part of Participants / Company.
21-09-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

 Gufic Biosciences Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
03-09-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

 Pursuant to Regulation 44(3) of SEBI (Listing Obligations And Disclosure Requirement) Regulations 2015, enclosed herewith are the details of voting results of the business transacted at the 38th Annual General Meeting (AGM) of the Company held on Friday, September 02, 2022 at 3:30 p.m., through Video Conferencing/Other Audio Visual Means, in the prescribed format along with the consolidated Report of the Scrutinizer on voting through electronic means (i.e., remote e-voting and voting at the AGM). You are requested to kindly take the same on record.
03-09-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Shareholder Meeting / Postal Ballot-Outcome of AGM

 Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the proceedings of the 38th Annual General Meeting of the Equity Shareholders of the Company held on Friday, September 2, 2022, through Video Conferencing/Other Audio Visual Means. You are requested to kindly take the same on record.
03-09-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 This is in continuation to our communication dated August 12, 2022 on Earning Conference Call and pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, written transcript of the said call held on August 12, 2022 at 4:30 p.m. has been uploaded on the Company's website and can be accessed through the link: http://gufic.com/Notice/Written%20Transcript%20120822.pdf Kindly take the same on record.
18-08-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the Earnings Conference Call held on August 12, 2022 at 4:30 p.m. has been uploaded on the Company's website and can be accessed through the link: http://gufic.com/Notice/AUDIORECORDING_12082022.mp3 Written transcript of the same will be submitted in due course. Kindly take the same on record.
12-08-2022
Bigul

Q1FY23 Quarterly Result Announced for Gufic BioSciences Ltd.

 Pharmaceuticals firm Gufic BioSciences announced Q1FY23 Result : Critical Care Division: Retained leadership position in Anti fungals & Anti bacterials Launch of Dual Chamber Bag initially targeting Anti-infectives. Addressable market size is ~Rs. 3,000 crores Critical Care segment faced headwinds due to reduced hospitalization and excess inventory in the channel. With the launch of Dual Chamber Bags and normalization of hospitalization we see growth coming back in the next few quarters Entered Neurology with unique products, with a special task force, and dedicated training center to broaden the addressable market Ferticare Division: Dydrogesterone: This product is ready for launch. To de-risk, we have vertically integrated with our own API. Market size for this product is ~Rs. 700 crores growing at 60% YoY. We as a Company are planning annual sales of Rs. 20 Crs. in less than 2 years Gufic has invested to develop recombinant alternatives to the urinary source of certain hormones which are critical in the treatment of infertility and thereby ensuring we will be independent of geopolitical as well as currency exchange risks and potential pitfalls in the next 15-18 months Having the widest basket of products along with vertically integrated manufacturing and strong field presence, we intend to be among the top 3 players in the next 3 years in infertility market that is around ~Rs. 4,000 Crs. and growing at 15% Result PDF
12-08-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation on Financial Results for the quarter ended June 30, 2022. Kindly take the same on record.
11-08-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Board Meeting Outcome for Outcome Of The Board Of Directors Meeting Held On Thursday, August 11, 2022

 Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') (including any statutory modification(s), amendment(s) and re-enactment(s) thereof), this is to inform that the Board of Directors of the Company at its Meeting held today i.e. Thursday, August 11, 2022, inter alia, considered and approved the Unaudited Financial Results along with the Limited Review Report for the quarter ended June 30, 2022, which has been duly reviewed and recommended by the Audit Committee. In this regard, we are enclosing herewith the following: 1. Un-Audited Financial Results for the Quarter ended June 30, 2022 2. Limited Review Report received from the Statutory Auditor of the Company on the Un-Audited Financial Results for the Quarter ended June 30, 2022. 3. Investor Presentation on the financial results.
11-08-2022
Next Page
Close

Let's Open Free Demat Account